Buy Sun Pharma; prefer Equitas Holdings: Kunj Bansal

Kunj Bansal of Centrum Wealth Management told CNBC-TV18, "In terms of SEBI’s guidelines, I am not ready with view but as the house we do cover Sun Pharmaceutical Industries and we clearly have a buy rating on the stock. We are quite comfortable about the company’s business model, financials and valuations. What we feel is that at the current price almost all the negatives are in the price. This positive news that has come yesterday may give it a short-term upside but other than that they may not be immediate short-term trigger but the stock is a good buy for medium and long term. Let us keep in mind that for the industry as a whole and for this stock, USFDA event continues to be a something which nobody can predict.""Just to add to the list, relatively less known name is Satin Creditcare. If we go into the long-term trend of the market whichever industry or sub segment of the industry, more and more opportunities keep becoming available for investing by investors and the valuations of the industry or of the one or two initial players which used to be above normal tend to come to the normal number one. Equitas Holdings is one share where we had bought post listing and we are continuing our position."